| __timestamp | Apellis Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 59644696 |
| Thursday, January 1, 2015 | 6356782 | 79541000 |
| Friday, January 1, 2016 | 4303743 | 98015000 |
| Sunday, January 1, 2017 | 10463151 | 103958000 |
| Monday, January 1, 2018 | 22639184 | 103654000 |
| Tuesday, January 1, 2019 | 67046483 | 128951000 |
| Wednesday, January 1, 2020 | 139401000 | 135799000 |
| Friday, January 1, 2021 | 176771000 | 149883000 |
| Saturday, January 1, 2022 | 277163000 | 220206000 |
| Sunday, January 1, 2023 | 500815000 | 265542000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Apellis Pharmaceuticals and Travere Therapeutics have shown distinct trends in their SG&A expenditures. From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase in SG&A costs, rising from approximately $3 million to over $500 million, marking a growth of over 16,000%. In contrast, Travere Therapeutics experienced a more moderate increase, with expenses growing from around $60 million to $266 million, a rise of about 340%.
While both companies have seen their SG&A costs rise, the rate of increase for Apellis Pharmaceuticals is significantly higher. This could indicate aggressive expansion strategies or inefficiencies in cost management. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these companies.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Travere Therapeutics, Inc. and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.